Physician profile
Thy P Nguyen
NPI 1932351707
$133,181.63
in general payments reported to CMS, 2019-2025
30 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $147 · 2021: $204 · 2022: $4,421 · 2023: $47K · 2024: $32K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Travel and Lodging: $8,106 · Consulting Fee: $6,505 · Food and Beverage: $5,042 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,977.50 |
| Travel and Lodging | $8,105.82 |
| Consulting Fee | $6,505.00 |
| Food and Beverage | $5,041.55 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $63,848.09 | 2023-2025 | Rystiggo, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $35,463.64 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $31,595.90 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Csl Behring | $412.73 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $337.18 | 2021-2025 | Hyqvia, Gammagard |
| Grifols USA, LLC | $281.56 | 2019-2022 | |
| Corium, LLC | $167.29 | 2023-2024 | Adlarity, Azstarys |
| Genzyme Corporation | $146.76 | 2023-2024 | |
| Greenwich Biosciences, INC. | $143.52 | 2019-2021 | |
| Acorda Therapeutics, INC | $103.18 | 2019 | |
| Biogen, INC. | $81.42 | 2021-2022 | |
| Abbvie INC. | $50.62 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $45.97 | 2025 | |
| Pfizer INC. | $43.61 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $41.19 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $41.14 | 2024 | |
| Janssen Biotech, INC. | $40.27 | 2025 | |
| Eisai INC. | $37.01 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $36.14 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $34.65 | 2022 | |
| Strongbridge US INC. | $32.59 | 2019-2020 | |
| Amgen INC. | $25.72 | 2019 | |
| Advanced Respiratory, INC | $25.70 | 2019 | |
| Adamas Pharmaceuticals, INC. | $24.92 | 2021 | |
| Averitas Pharma INC. | $22.43 | 2024 | Qutenza |
| Lilly USA, LLC | $22.15 | 2022 | |
| Neurocrine Biosciences, INC. | $21.98 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $21.49 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $16.65 | 2024 | Wainua |
| Tanabe Pharma America, INC. | $16.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thy Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.